The vulnerability to alcohol and substance abuse in individuals diagnosed with schizophrenia

Neurotoxicity Research

Volumn 10, Issue 3-4, 2006, Pages 235-252

  Krystal, John H ^a,b,c   D'Souza, Cyril ^a,b,c   Gallinat, Jürgen ^d   Driesen, Naomi ^a,b   Abi Dargham, Anissa ^e   Petrakis, Ismene ^a,b   Heinz, Andreas ^d   Pearlson, Godfrey ^a,f  

^a YALE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b VA CONNECTICUT HEALTHCARE SYSTEM   (United States)

^c Yale University School of Medicine   (United States)

^d CHARITÉ UNIVERSITÄTSMEDIZIN BERLIN   (Germany)

^e NEW YORK STATE PSYCHIATRIC INSTITUTE   (United States)

^f INSTITUTE OF LIVING   (United States)

Author keywords

Alcoholism; Dopamine; Dual diagnosis; Frontal cortex; GABA; Glutamate; Hippocampus; Schizophrenia; Striatum; Substance abuse; Vulnerability

Indexed keywords

ADDICTION; ALCOHOLISM; COMORBIDITY; GENETICS; HUMAN; MOTIVATION; PSYCHIATRIC DIAGNOSIS; PSYCHOLOGICAL ASPECT; PSYCHOLOGY; REVIEW; RISK; SCHIZOPHRENIA;

ALCOHOLISM; COMORBIDITY; DIAGNOSIS, DUAL (PSYCHIATRY); HUMANS; MOTIVATION; RISK; SCHIZOPHRENIA; SCHIZOPHRENIC PSYCHOLOGY; SUBSTANCE-RELATED DISORDERS;

EID: 33947495416     PISSN: 10298428     EISSN: None     Source Type: Journal    
DOI: 10.1007/BF03033360     Document Type: Article

References (169)

1. Abi-Dargham A, R Gil, J Krystal, RM Baldwin, JP Seibyl, M Bowers, CH van Dyck, DS Charney, RB Innis and M Laruelle (1998) Increased striatal dopamine transmission in schizophrenia: Confirmation in a second cohort. Am. J. Psychiatry 155, 761-767.
2. 2 receptors by dopamine in schizophrenia. Proc. Natl. Acad. Sci. USA. 97, 8104-8109.
3. Abi-Dargham A, LS Kegeles, D Martinez, RB Innis and M Laruelle (2003) Dopamine mediation of positive reinforcing effects of amphetamine in stimulant naive healthy volunteers: Results from a large cohort. Eur. Neuropsychopharmacol. 13, 459-468.
4. Anthony JC, LA Warner and RC Kessler (1994) Comparative epidemiology of dependence on tobacco, alcohol, controlled substances, and inhalants: basic findings from the National Comorbidity Survey. Exp. Clin. Psychopharmacol. 2, 244-268.
5. Baron M, R Gruen, JD Rainer, J Kane, L Asnis and S Lord (1985) A family study of schizophrenic and normal control probands: Implications for the spectrum concept of schizophrenia. Am. J. Psychiatry 142, 477-455.
6. Bartels SJ, GB Teague, RE Drake, RE Clark, PW Bush and DL Noordsy (1993) Substance abuse in schizophrenia: Service utilization and costs. J. Nerv. Ment. Dis. 181, 227-232.
7. Bechara A, H Damasio and AR Damasio (2000a) Emotion, decision making and the orbitofrontal cortex. Cereb. Cortex. 10, 295-307.
8. Bechara A, D Tranel and H Damasio (2000b) Characterization of the decision-making deficit of patients with ventromedial prefrontal cortex lesions. Brain 123, 2189-2202.
9. Bechara A, S Dolan, N Denburg, A Hindes, SW Anderson and PE Nathan (2001) Decision-making deficits, linked to a dysfunctional ventromedial prefrontal cortex, revealed in alcohol and stimulant abusers. Neuropsychologia 39, 376-389.
10. Bechara A, S Dolan and A Hindes (2002) Decision-making and addiction (part II): Myopia for the future or hypersensitivity to reward? Neuropsychologia 40, 1690-1705.
11. Beninger RJ, J Wasserman, K Zanibbi, D Charbonneau, J Mangels and BV Beninger (2003) Typical and atypical antipsychotic medications differentially affect two nondeclarative memory tasks in schizophrenic patients: A double dissociation. Schizophr. Res. 61, 281-292.
12. Bidaut-Russell M, EM Smith and SE Bradford (1994) Gender differences in lifetime psychiatric disorders between sons and daughters of alcoholic mothers: A pilot study. Alcoholism, Clin. Exp. Res. 18, 244-247.
13. Bilder RM, B Bogerts, M Ashtari, H Wu, JM Alvir, D Jody, G Reiter, L Bell and JA Lieberman (1995) Anterior hippocam pal volume reductions predict frontal lobe dysfunction in first episode schizophrenia. Schizophr. Res. 17, 47-58.
14. Bjork JM, B Knutson, GW Fong, DM Caggiano, SM Bennett and DW Hommer (2004) Incentive-elicited brain activation in adolescents: Similarities and differences from young adults. J. Neurosci 24, 1793-1802.
15. Blanchard JJ, SA Brown, WP Horan and AR Sherwood (2000) Substance use disorders in schizophrenia: Review, integration, and a proposed model. Clin. Psychol. Rev. 20, 207-234.
16. Brecher M and H Begleiter (1983) Event-related brain potentials to high-incentive stimuli in unmedicated schizophrenic patients. Biol Psychiatry 18, 661-674.
17. Breese CR, MJ Lee, CE Adams, B Sullivan, J Logel, KM Gillen, MJ Marks, AC Collins and S Leonard (2000) Abnormal regulation of high affinity nicotinic receptors in subjects with schizophrenia. Neuropsychopharmacol 23, 351-364.
18. Breier A, TP Su, R Saunders, RE Carson, BS Kolachana, A de Bartolomeis, DR Weinberger, N Weisenfeld, AK Malhotra, WC Eckelman and D Pickar (1997) Schizophrenia is associated with elevated amphetamine-induced synaptic dopamine concentrations: Evidence from, a novel positron emission tomography method. Proc. Natl. Acad. Sci. USA 94, 2569- 2574.
19. Brunette MF, KT Mueser, H Xie and RE Drake (1997) Relationships between symptoms of schizophrenia and substance abuse. J. Nerv. Ment. Dis. 185, 13-20.
20. Bryson G, M Bell, E Kaplan, T Greig and P Lysaker (1998) Affect recognition in deficit syndrome schizophrenia. Psychiatry Res. 77, 113-120.
21. Bussey TJ, BJ Everitt and TW Robbins (1997) Dissociable effects of cingulate and medial frontal cortex lesions on stimulus-reward learning using a novel Pavlovian autoshaping procedure for the rat: Implications for the neurobiology of emotion. Behav. Neurosci 111, 908-919.
22. Cantor-Graae E, LG Nordstrom and TF McNeil (2001) Substance abuse in schizophrenia: A review of the literature and a study of correlates in Sweden. Schizophr. Res. 48, 69-82.
23. Cardinal RN, JA Parkinson, J Hall and BJ Everitt (2002) Emotion and motivation: The role of the amygdala, ventral striatum, and prefrontal cortex. Neurosci. Biobehav. Rev. 26, 321-352.
24. Carpenter WT Jr, DW Heinrichs and AM Wagman (1988) Deficit and nondeficit forms of schizophrenia: The concept. Am. J. Psychiatry 145, 578-583.
25. Chambers RA, JH Krystal and DW Self (2001) A neurobiological basis for substance abuse comorbidity in schizophrenia. Biol. Psychiatry 50, 71-83.
26. Clark DB, J Cornelius, DS Wood and M Vanyukov (2004) Psychopathology risk transmission in children of parents with substance use disorders. Am. J. Psychiatry 161, 685-691.
27. Cohen BD (1956) Motivation and performance in schizophrenia. J. Abnormal Social Psychol. 52, 186-190.
28. Crespo-Facorro B, S Paradiso, NC Andreasen, DS O'Leary, GL Watkins, LL Ponto and RD Hichwa (2001) Neural mechanisms of anhedonia in schizophrenia: A PET study of response to unpleasant and pleasant odors. JAMA 286, 427-435.
29. Cromwell HC and W Schultz (2003) Effects of expectations for different reward magnitudes on neuronal activity in primate striatum. J. Neurophysiol. 89, 2823-2838.
30. D'Souza DC, WM Abi-Saab, S Madonick, K Forselius-Bielen, A Doersch, G Braley, R Gueorguieva, TB Cooper and JH Krystal (2005) Delta-9-tetrahydrocannabinol effects in schizophrenia: Implications for cognition, psychosis, and addiction. Biol. Psychiatry 57, 594-608.
31. Dao-Castellana MH, ML Paillere-Martinot, P Hantraye, D Attar-Levy, P Remy, C Crouzel, E Artiges, A Feline, A Syrota and JL Martinot (1997) Presynaptic dopaminergic function in the striatum of schizophrenic patients. Schizophr. Res. 23, 167-174.
32. Deakin JF and MD Simpson (1997a) A two-process theory of schizophrenia: evidence from studies in post-mortem brain. J. Psychiatric Res. 31, 277-295.
33. Deakin JF and MD Simpson (1997b) A two-process theory of schizophrenia: evidence from studies in post-mortem brain. J. Psychiatric Res. 31, 277-295.
34. DeQuardo JR, CF Carpenter and R Tandon (1994) Patterns of substance abuse in schizophrenia: Nature and significance. J. Psychiatric Res. 28, 267-275.
35. Dervaux A, FJ Bayle, X Laqueille, MC Bourdel, MH Le Borgne, JP Olie and MO Krebs (2001) Is substance abuse in schizophrenia related to impulsivity, sensation seeking, or anhedonia? Am. J. Psychiatry 158, 492-494.
36. Dervaux A, FJ Bayle, X Laqueille, MC Bourdel, MH Le Borgne, JP Olie and MO Krebs (2004) Nicotine use in schizophrenia and disinhibition. Psychiatry Res. 128, 229- 234.
37. Dixon L (1999) Dual diagnosis of substance abuse in schizophrenia: prevalence and impact on outcomes. Schizophr. Res. 35, S93-S100.
38. Dixon L, G Haas, P Weiden, J Sweeney and A Frances (1990) Acute effects of drug abuse in schizophrenic patients: Clinical observations and patients' self-reports. Schizophr. Bull. 16, 69-79.
39. Dixon L, G Haas, PJ Weiden, J Sweeney and AJ Frances (1991) Drug abuse in schizophrenic patients: Clinical correlates and reasons for use. Am. J. Psychiatry 148, 224-230.
40. Drake RE, MA Wallach, HS Alverson and KT Mueser (2002) Psychosocial aspects of substance abuse by clients with severe mental illness. J. Nerv. Ment. Dis. 190, 100-106.
41. Duke PJ, C Pantelis, MA McPhillips and TR Barnes (2001) Comorbid non-alcohol substance misuse among people with schizophrenia: epidemiological study in central London. Brit. J. Psychiatry 179, 509-513.
42. 18F]DOPA PET study in patients with schizophrenia. Positron emission tomography. Psychiatry Res. 100, 1-11.
43. Epstein EE, BE Ginsburg, VM Hesselbrock and JC Schwarz (1994) Alcohol and drug abusers subtyped by antisocial personality and primary or secondary depressive disorder. Ann. NY Acad. Sci. 708, 187-201.
44. Erlenmeyer-Kimling L, UH Adamo, D Rock, SA Roberts, AS Bassett, E Squires-Wheeler, BA Cornblatt, J Endicott, S Pape and II Gottesman (1997) The New York High-Risk Project. Prevalence and comorbidity of axis I disorders in offspring of schizophrenic parents at 25-year follow-up. Arch. Gen. Psychiatry 54, 1096-1102.
45. Everitt BJ, JA Parkinson, MC Olmstead, M Arroyo, P Robledo and TW Robbins (1999) Associative processes in addiction and reward. The role of amygdala-ventral striatal subsystems. Ann. NY Acad. Sci. 877, 412-438.
46. Fenton WS and TH McGlashan (1994) Antecedents, symptom progression, and long-term outcome of the deficit syndrome in schizophrenia. Am. J. Psychiatry 151, 351-356.
47. Fenton WS, CR Blyler and RK Heinssen (1997) Determinants of medication compliance in schizophrenia: Empirical and clinical findings. Schizophr. Bull. 23, 637-651.
48. Fiorillo CD, PN Tobler and W Schultz (2003) Discrete coding of reward probability and uncertainty by dopamine neurons. Science 299, 1898-1902.
49. Fowler RC, MT Tsuang, RJ Cadoret and E Monnelly (1975) Non-psychotic disorders in the families of process of schizophrenics. Acta Psychiatr. Scand. 51, 153-160.
50. 7 nicotinic acetylcholine receptor subunit gene (CHRNA7). Am. J. Med Genet. 105, 20-22.
51. Freudenreich O, C Gather, AE Evins, DC Henderson and DC Goff (2004) Attitudes of schizophrenia outpatients toward psychiatric medications: relationship to clinical variables and insight. J. Clin. Psychiatry 65, 1372-1376.
52. Frye MA, LL Altshuler, SL McElroy, T Suppes, PE Keck, K Denicoff, WA Nolen, R Kupka, GS Leverich, C Pollio, H Grunze, J Waiden and RM Post (2003) Gender differences in prevalence, risk, and clinical correlates of alcoholism comorbidity in bipolar disorder. Am. J. Psychiatry 160, 883-889.
53. Galen LW, KJ Brower, BW Gillespie and RA Zucker (2000) Sociopathy, gender, and treatment outcome among outpatient substance abusers. Drug Alcohol Depend. 61, 23-33.
54. Gao XM, K Sakai, RC Roberts, RR Conley, B Dean and CA Tamminga (2000) lonotropic glutamate receptors and expression of N-methyl-D-aspartate receptor subunits in subregions of human hippocampus: Effects of schizophrenia. Am. J. Psychiatry 157, 1141-1149.
55. Garmezy N (1952) Stimulus differentiation by schizophrenic and normal subjects under conditions of reward and punishment. J. Personality 20, 253-276.
56. Gearon JS, AS Bellack, J Rachbeisel and L Dixon (2001) Drug-use behavior and correlates in people with schizophrenia. Addict. Behav. 26, 51-61.
57. Gearon JS, SI Kaltman, C Brown and AS Bellack (2003) Traumatic life events and PTSD among women with substance use disorders and schizophrenia. Psychiatr. Serv. 54, 523-528.
58. George TP, JC Vessicchio, A Termine, DM Sahady, CA Head, WT Pepper, TR Kosten and BE Wexler (2002) Effects of smoking abstinence on visuospatial working memory function in schizophrenia. Neuropsychopharmacol. 26, 75-85.
59. Gershon ES, LE DeLisi, J Hamovit, JI Nurnberger Jr. ME Maxwell, J Schreiber, D Dauphinais, CW Dingman 2nd and JJ Guroff (1988) A controlled family study of chronic psychoses. Schizophrenia and schizoaffective disorder. Arch. Gen Psychiatry 45, 328-336.
60. Goldstein RZ, ND Volkow, GJ Wang, JS Fowler and S Rajaram (2001) Addiction changes orbitofrontal gyrus function: Involvement in response inhibition. Neuroreport 12, 2595-2999.
61. Goswami S, SK Mattoo, D Basu and G Singh (2004) Substanceabusing schizophrenics: Do they self-medicate? Am. J. Addict 13, 139-150.
62. Goto Y and P O'Donnell (2002) Delayed mesolimbic system alteration in a developmental animal model of schizophrenia. J. Neurosci. 22, 9070-9077.
63. Grant KA and G Colombo (1993) Discriminative stimulus effects of ethanol: Effect of training dose on the substitution of N -methyl-D-aspartate antagonists. J. Pharmacol Exp. Ther 264, 1241-1247.
64. Green AI, SV Zimmet, RD Strous and JJ Schildkraut (1999) Clozapine for comorbid substance use disorder and schizophrenia: Do patients with schizophrenia have a primary reward-deficiency syndrome that can be ameliorated by clozapine? Harvard Rev. Psychiatry 6, 287-296.
65. Hafner H, K Maurer, G Trendler, Wan der Heiden, M Schmidt and R Konnecke (2005) Schizophrenia and depression: Challenging the paradigm of two separate diseases - a controlled study of schizophrenia, depression and healthy controls. Schizophr. Res. 77, 11-24.
66. Heath AC, PA Madden, KK Bucholz, SH Dinwiddie, WS Slutske, LJ Bierut, JW Rohrbaugh, DJ Statham, MP Dunne, JB Whitfield and NG Martin (1999) Genetic differences in alcohol sensitivity and the inheritance of alcoholism risk. Psychol Med. 29, 1069-1081.
67. Heinz A (1999) [Psychopathological correlates of dopaminergic dysfunction in alcoholic and schizophrenic patients]. Nervernarzt. 70, 399-407.
68. Heinz A, S Lober, A Georgi, J Wrase, D Hermann, ER Rey, S Wellek and K Mann (2003) Reward craving and withdrawal relief craving: Assessment of different motivational pathways to alcohol intake. Alcohol Alcoholism 38, 35-39.
69. 2 receptors in the ventral striatum and central processing of alcohol cues and craving. Am. J. Psychiatry 161, 1783-1789.
70. 18 F]DOPA and [F]DMFP PET study in detoxified alcoholic patients. Am. J Psychiatry 162, 1515-1520.
71. Hesselbrock MN and VM Hesselbrock (1992) Relationship of family history, antisocial personality disorder and personality traits in young men at risk for alcoholism. J. Studies Alcohol 53, 619-625.
72. Hommer DW, B Knutson, GW Fong, S Bennett CM Adams and JL Varnera (2003) Amygdalar recruitment during anticipation of monetary rewards: An event-related fMRI study. Ann. NYAcad Sci. 985, 476-478.
73. Hurwitz T, L Kopala, C Clark and B Jones (1988) Olfactory deficits in schizophrenia. Biol. Psychiatry 23, 123-128.
74. Jacobsen LK, DC D'Souza, WE Mend, KR Pugh, P Skudlarski and JH Krystal (2004) Nicotine effects on brain function and functional connectivity in schizophrenia. Biol. Psychiatry 55, 850-858.
75. Juckel G, L Sass and A Heinz (2003) Anhedonia, self-experience in schizophrenia, and implications for treatment. Pharmacopsychia-try 36, S176-S180.
76. Juckel G, F Schlagenhauf, M Koslowski, T Wüstenberg, A Villringer, B Knutson, J Wrase and A Heinz(2005) Dysfunction of ventral striatal reward prediction in schizophrenia. Neuroimage E-publication ahead of print.
77. 2receptor occupancy of clozapine, risperidone, and olanzepine in schizophrenia. Am. J. Psychiatry 156, 286-293.
78. Kavanagh DJ, J McGrath, JB Saunders, G Dore and D Clark (2002) Substance misuse in patients with schizophrenia: Epidemiology and management. Drugs 62, 743-755.
79. Kegeles LS, DC Shungu, S Anjilvel, S Chan, SP Ellis, E Xanthopoulos, D Malaspina, JM Gorman, JJ Mann, M Lamelle and CA Kaufmann (2000) Hippocampal pathology in schizophrenia: Magnetic resonance imaging and spectros- copy studies. Psychiatiy Res. 98, 163-175.
80. Kendler KS (1985) A twin study of individuals with both schizophrenia and alcoholism. Brit. J. Psychiatry 147, 48-53.
81. Kendler KS and CO Gardner (1997) The risk for psychiatric disorders in relatives of schizophrenic and control probands: A comparison of three independent studies. Psychol Med. 27,411-419.
82. Kendler KS and P Hays (1983) Schizophrenia subdivided by the family history of affective disorder. A comparison of symptomatology and course of illness. Arch. Gen. Psychiatry 40, 951-955.
83. Kendler KS, AM Gruenberg and JS Strauss (1981) An independent analysis of the Copenhagen sample of the Danish adoption study of schizophrenia. I. The relationship between anxiety disorder and schizophrenia. Arch. Gen. Psychiatry 38, 973-977.
84. Kendler KS, AM Gruenberg and JS Strauss (1982) An independent analysis of the Copenhagen sample of the Danish adoption study of schizophrenia. IV. The relationship between major depressive disorder and schizophrenia. Arch. Gen. Psychiatry 39, 639-642.
85. Kendler KS, AM Gruenberg and MT Tsuang (1985a) Psychiatric illness in first-degree relatives of schizophrenic and surgical control patients. A family study using DSM-III criteria. Arch. Gen. Psychiatry 42, 770-779.
86. Kendler KS, CC Masterson and KL Davis (1985b) Psychiatric illness in first-degree relatives of patients with paranoid psychosis, schizophrenia and medical illness. Brit. J. Psychiatry 147, 524-531.
87. Kendler KS, M McGuire, AM Gruenberg, A O'Hare, M Spellman and D Walsh (1993) The Roscommon Family Study. IV. Affective illness, anxiety disorders, and alcohol ism in relatives. Arch. Gen. Psychiatry 50, 952-960.
88. Kendler KS, M McGuire, AM Gruenberg and D Walsh (1994) Clinical heterogeneity in schizophrenia and the pattern of psychopathology in relatives: Results from an epidemiologically based family study. Acta Psychiatr. Scand. 89, 294-300.
89. Kendler KS, M McGuire, AM Gruenberg and D Walsh (1995) Examining the validity of DSM-III-R schizoaffective disorder and its putative subtypes in the Roscommon Family Study. Am. J. Psychiatry 152, 755-764.
90. Kendler KS, L Karkowski-Shuman and D Walsh (1996) The risk for psychiatric illness in siblings of schizophrenics: The impact of psychotic and non-psychotic affective illness and alcoholism in parents. Acta Psychiatr. Scand. 94, 49-55.
91. Khantzian EJ (1997) The self-medication hypothesis of substance use disorders: A reconsideration and recent applications [see comments]. Harvard Rev. Psychiatiy 4, 231-244.
92. Khantzian EJ, JE Mack and AF Schatzberg (1974) Heroin use as an attempt to cope: Clinical observations. Am. J. Psychiatry 131, 160-164.
93. Kirkpatrick B, XF Amador, M Flaum, SA Yale, JM Gorman, WT Carpenter Jr, M Tohen and T McGlashan (1996) The deficit syndrome in the DSM-IV Field Trial: I. Alcohol and other drug abuse. Schizophr. Res. 20, 69-77.
94. Knutson B, CM Adams, GW Fong and D Hommer (2001a) Anticipation of increasing monetary reward selectively recruits nucleus accumbens. J. Neurosci. 21, RC159.
95. Knutson B, GW Fong, CM Adams, JL Varner and D Hommer (2001b) Dissociation of reward anticipation and outcome with event-related fMRI. Neuroreport 12, 3683-3687.
96. Knutson B, GW Fong, CM Adams, JL Varner and D Hommer (2001c) Dissociation of reward anticipation and outcome with event-related fMRI. Neuroreport 12, 3683-3687.
97. Knutson B, GW Fong, SM Bennett, CM Adams and D Hommer (2003) A region of mesial prefrontal cortex tracks monetarily rewarding outcomes: characterization with rapid event-related fMRI. Neuroimage 18, 263-272.
98. Knutson B, JM Bjork, GW Fong, D Hommer, VS Mattay and DR Weinberger (2004) Amphetamine modulates human incentive processing. Neuron 43, 261-269.
99. Krystal H and HA Raskin (1970) Drug Dependence: Aspects of Ego Functions (Wayne State University Press:WAyne State University).
100. Krystal JH, IL Petrakis, E Webb, NL Cooney, LP Karper, S Namanworth, P Stetson, LA Trevisan and DS Charney (1998) Dose-related ethanol-like effects of the NMDA antagonist, ketamine, in recently detoxified alcoholics. Arch. Gen. Psychiatry 55, 354-360.
101. Krystal JH, DC D'Souza, S Madonick and IL Petrakis (1999) Toward a rational pharmacotherapy of comorbid substance abuse in schizophrenic patients. Schizophr. Res. 35 suppl, S35-S49.
102. Krystal JH, JA Cramer, W Kroll, G Kirk, RA Rosenheck and Group VANCS (2001) Naltrexone in the treatment of alcohol dependence. N Engl. J. Med 345, 1734-1739.
103. Krystal JH and B Tabakoff (2002) Ethanol abuse, dependence, and withdrawal: Neurobiology and clinical implications, In: Psychopharmacology: A Fifth Generation of Progress (Davis KL, DS Charney, JT Coyle and C Nemeroff, Eds.) (Lippincott Williams and Wilkins: Philadelphia), pp 1425-1443.
104. Krystal JH, DC D'Souza, D Mathalon, E Perry, A Beiger and RE Hoffman (2003 a) NMDA receptor antagonist effects, cortical glutamatergic function, and schizophrenia: Toward a paradigm shift in medication development. Psychopharmacology 169, 215-233.
105. Krystal JH, IL Petrakis, D Limoncelli, E Webb, R Gueorguieva, DC D'Souza, NN Boutros, L Trevisan and DS Charney (2003b) Altered NMDA glutamate receptor antagonist response in recovering ethanol dependent patients. Neuropsychopharmacol. 28, 2020-2028.
106. Krystal JH, IL Petrakis, L Trevisan and DC D'Souza (2003c) NMDA receptor antagonism and the ethanol intoxication signal: From alcoholism risk to pharmacotherapy. Ann. NY Acad. Sci 1003, 176-184.
107. Kurs R, H Farkas and M Ritsner (2005) Quality of life and temperament factors in schizophrenia: Comparative study of patients, their siblings and controls. Quality Life Res. 14, 433-440.
108. Lambert M, C Haasen, R Mass and M Krausz (1997) [Consumption patterns and motivation for use of addictive drugs in schizophrenic patients]. Psychiatric Praxis 24, 185-189.
109. Lamelle M, A Abi-Dargham, CH van Dyck, R Gil, CD D'Souza, J Erdos, E McCance, W Rosenblatt, C Fingado, SS Zoghbi, RM Baldwin, JP Seibyl, JH Krystal, DS Charney and RB Innis (1996) Single photon emission computerized tomography imaging of amphetamine-induced dopamine release in drug-free schizophrenic subjects. Proc. Natl. Acad. Sci USA 93, 9235-9240.
110. Lamelle M, A Abi-Dargham, R Gil, L Kegeles and R Innis (1999) Increased dopamine transmission in schizophrenia: Relationship to illness phases. Biol. Psychiatry 46, 56-72.
111. Layne C and LT Wallace (1982) Impaired preferences for praise in schizophrenic adolescents. J. Clin. Psychology 38, 51-55.
112. Leonard S, C Breese, C Adams, K Benhammou, J Gault, K Stevens, M Lee, L Adler, A Olincy, R Ross and R Freedman (2000) Smoking and schizophrenia: abnormal nicotinic receptor expression. Eur. J. Pharmacol 393, 237-242.
113. Lyons MJ, JL Bar, WS Kremen, R Toomey, SA Eisen, J Goldberg, SV Faraone and M Tsuang (2002) Nicotine and familial vulnerability to schizophrenia: A discordant twin study. J. Abnormal PsychoL 111, 687-693.
114. Lysaker P, M Bell, J Beam-Goulet and R Milstein (1994) Relationship of positive and negative symptoms to cocaine abuse in schizophrenia. J. Nerv. Ment. Dis. 182, 109-112.
115. Martin-Solch C, S Magyar, G Kunig, J Missimer, W Schultz and KL Leenders (2001) Changes in brain activation associated with reward processing in smokers and nonsmokers. A positron emission tomography study. Exp. Brain Res. 139, 278-286.
116. 2 receptor availability in the functional subdivisions of the striatum: Relationship with cocaine-seeking behavior. Neuropsychopharmacol. 29, 1190-1202.
117. Martinez D, R Gil, M Slifstein, D-R Hwang, Y Huang, A Perez, L Kegeles, S Evans, JH Krystal and M Laraelle (2005) Alcohol dependence is associated with blunting of dopamine transmission in the ventral striatum. Biol. Psychiatry. E-publication ahead of press.
118. McReadie RG and SCS Group (2002) Use of drags, alcohol, and tobacco by people with schizophrenia: Case-control study. Brit. J. Psychiatry 181, 321-325.
119. Meador-Woodruff JH and DJ Healy (2000) Glutamate receptor expression in schizophrenic brain. Brain Res. Brain Res. Rev. 31, 288-294.
120. Melendez RI, ZA Rodd-Henricks, EA Engleman, TK Li, WJ McBride and JM Murphy (2002) Microdialysis of dopamine in the nucleus accumbens of alcohol-preferring (P) rats during anticipation and operant self-administration of ethanol. Alcoholism: Clin. Exp. Res. 26, 318-325.
121. Merikangas KR and S Avenevoli (2000) Implications of genetic epidemiology for the prevention of substance use disorders. Addict. Behav. 25, 807-820.
122. Mexal S, M Frank, R Berger, CE Adams, RG Ross, R Freedman and S Leonard (2005) Differential modulation of gene expression in the NMDA postsynaptic density of schizophrenic and control smokers. Brain Res. Mol. Brain Res. 139, 317-332.
123. Mueser KT, PR Yarnold, DF Levinson, H Singh, AS Bellack, K Kee, RL Morrison and KG Yadalam (1990) Prevalence of substance abuse in schizophrenia: Demographic and clinical correlates. Schizophr. Bull. 16, 31-56.
124. Mueser KT, P Nishith, JI Tracy, J DeGirolamo and M Molinaro (1995) Expectations and motives for substance use in schizophrenia. Schizophr. Bull. 21, 367-378.
125. Mueser KT, RE Drake, TH Ackerson, AI Alterman, KM Miles and DL Noordsy (1997) Antisocial personality disorder, conduct disorder, and substance abuse in schizophrenia. J. Abnormal Psychol 106, 473-477.
126. Mueser KT, SD Rosenberg, RE Drake, KM Miles, G Wolford, R Vidaver and K Carrieri (1999) Conduct disorder, antisocial personality disorder and substance use disorders in schizophrenia and major affective disorders. J. Studies Alcohol 60, 278-284.
127. Mueser KT, SD Rosenberg, LA Goodman and SL Trumbetta (2002) Trauma, PTSD, and the course of severe mental illness: An interactive model. Schizophr. Res. 53, 123-143.
128. Noordsy DL, RE Drake, JC Biesanz and GJ McHugo (1994) Family history of alcoholism in schizophrenia. J. Nerv. Ment. Dis. 182, 651-655.
129. Noordsy DL and AI Green (2003) Pharmacotherapy for schizophrenia and co-occurring substance use disorders. Curr. Psychiatry Rep. 5, 340-346.
130. Nurnberger JIJ, R Wiegand, K Bucholz, S O'Connor, ET Meyer, T Reich, J Rice, M Schuckit, L King, T Petti, L Bierut, AL Hinrichs, S Kuperman, V Hesselbrock and B Porjesz (2004) A family study of alcohol dependence: coag- gregation of multiple disorders in relatives of alcohol-dependent probands. Arch. Gen. Psychiatry 61, 1246-1256.
131. O'Brien CP, DS Charney, L Lewis, JW Cornish, RM Post, GE Woody, JK Zubieta, JC Anthony, JD Blaine, CL Bowden, JR Calabrese, K Carroll, T Kosten, B Rounsaville, AR Childress, DW Oslin, HM Pettinati, MA Davis, R Demartino, RE Drake, MF Fleming, L Fricks, AH Glassman, FR Levin, EV Nunes, RL Johnson, C Jordan, RC Kessler, SK Laden, DA Regier, JAJ Renner, RK Ries, T Sklar-Blake and C Weisner (2004) Priority actions to improve the care of persons with co-occurring substance abuse and other mental disorders: A call to action. Biol. Psychiatry 56, 703-713.
132. O'Donnell P and AA Grace (1995) Synaptic interactions among excitatory afferents to nucleus accumbens neurons: Hippocampal gating of prefrontal cortical input. J. Neurosci. 15, 3622-3639.
133. O'Donnell P and AA Grace (1998) Phencyclidine interferes with the hippocampal gating of nucleus accumbens neuronal activity in vivo. Neuroscience 87, 823-830.
134. Petrakis IL, D Limoncelli, R Gueorguieva, P Jatlow, NN Boutros, L Trevisan, J Gelernter and JH Krystal (2004a) Altered NMDA glutamate receptor antagonist response in individuals with a family vulnerability to alcoholism. Am. J. Psychiatry 161, 1776-1782.
135. Petrakis IL, S O'Malley, B Rounsaville, J Poling, C McHughStrong and JH Krystal (2004b) Naltrexone augmentation of neuroleptic in alcohol-abusing schizophrenic patients. Psychopharmacology 111, 291-297.
136. Petry NM (2002) Discounting of delayed rewards in substance abusers: relationship to antisocial personality disorder. Psychopharmacology 162, 425-432.
137. Petry NM, KN Kirby and HR Kranzler (2002) Effects of gender and family history of alcohol dependence on a behavioral task of impulsivity in healthy subjects. J. Studies Alcohol 63, 83-90.
138. Pierri JN, AS Chaudry, TU Woo and DA Lewis (1999) Alterations in chandelier neuron axon terminals in the prefrontal cortex of schizophrenic subjects. Am. J. Psychiatry 156, 1709-1719.
139. Pilowsky LS, RA Bressan, JM Stone, K Erlandsson, RS Mulligan, JH Krystal and PJ Ell (2006) First in vivo evidence of an NMDA receptor deficit in medication-free schizophrenic patients. Mol. Psychiatry 11, 118-119.
140. Pollock VE (1992) Meta-analysis of subjective sensitivity to alcohol in sons of alcoholics. Am. J. Psychiatry 149, 1534- 1538.
141. Regier DA, ME Farmer, DS Rae, BZ Locke, SJ Keith, LL Judd and FK Goodwin (1990) Comorbidity of mental disorders with alcohol and other drag abuse. Results from the Epidemiologie Catchment Area (EGA) Study. JAMA 264, 2511-2518.
142. Reith J, C Benkelfat, A Sherwin, Y Yasuhara, H Kuwabara, F Andermann, S Bachneff, P Gumming, M Diksic, SE Dyve et al. (1994) Elevated dopa decarboxylase activity in living brain of patients with psychosis. Proc. Natl. Acad. Sci USA. 91, 11651-11654.
143. Resnick SG, GR Bond and KT Mueser (2003) Trauma and posttraumatic stress disorder in people with schizophrenia. J. Abnormal Psychol. 112, 415-423.
144. Ritter LM, JH Meador-Woodruff and GW Dalack (2004) Neurocognitive measures of prefrontal cortical dysfunction in schizophrenia. Schizophr Res. 68, 65-73.
145. Robbins TW and BJ Everitt (1996) Neurobehavioural mechanisms of reward and motivation. Curr. Opin. Neurobiol. 6, 228-236.
146. Rogers RD, BJ Everitt, A Baldacchino, AJ Blackshaw, R Swainson, K Wynne, NB Baker, J Hunter, T Carthy, E Booker, M London, JF Deakin, BJ Sahakian and TW Robbins (1999) Dissociable deficits in the decision-making cognition of chronic amphetamine abusers, opiate abusers, patients with focal damage to prefrontal cortex, and tryptophan-depleted normal volunteers: Evidence for monoaminergic mechanisms. Neuropsychopharmacol. 20, 322-339.
147. Rolls ET (1999) The Brain and Emotion (Oxford University Press: Oxford).
148. Sacco KA, A Termine, A Seyal, MM Dudas, JC Vessicchio, S Krishnan-Sarin, PI Jatlow, BE Wexler and T George, (2005) Effects of cigarette smoking on spatial working memory and attentional deficits in schizophrenia: involvement of nicotinic receptor mechanisms. Arch. Gen. Psychiatry 62, 649-659.
149. Scheller-Gilkey G, K Moynes, I Cooper, C Kant and AH Miller (2004) Early life stress and PTSD symptoms in patients with comorbid schizophrenia and substance abuse. Schizophr. Res. 69, 167-174.
150. Schneier FR and SG Siris (1987) A review of psychoactive substance use and abuse in schizophrenia. Patterns of drug choice. J. Nerv. Ment. Dis. 175, 641-652.
151. Schuckit MA (1994) Low level of response to alcohol as a predictor of future alcoholism. Am. J. Psychiatry 151, 184- 189.
152. Schuckit MA and TL Smith (1996) An 8-year follow-up of 450 sons of alcoholic and control subjects. Arch. Gen. Psychiatry 53, 202-210.
153. Schultz W (1998) Predictive reward signal of dopamine neurons. J. Neurophysiol. 80, 1-27.
154. Seibyl JP, SL Satel, D Anthony, SM Southwick, JH Krystal and DS Charney (1993) Effects of cocaine on hospital course in schizophrenia. J. Nerv. Ment. Dis. 181, 31-37.
155. Seidman LJ, NL Talbot, AG Kalinowski, RW McCarley, SV Faraone, WS Kremen, JR. Pepple and MT Tsuang (1991) Neuropsychological probes of fronto-limbic system dys-function in schizophrenia, olfactory identification and Wisconsin Card Sorting performance. Schizophr. Res. 6, 55-65.
156. Shurman B, WP Horan and KH Neuchterlein (2005) Schizophrenia patients
157. Sibitz I, H Katschnig, R Goessler, A Unger and M Amering (2005) Pharmacophilia and pharmacophobia: Determinants of patients' attitudes towards antipsychotic medication. Pharmacopsychiatry 3, 107-112.
158. Spring B, R Pingitore and DE McChargue (2003) Reward value of cigarette smoking for comparably heavy smoking schizophrenic, depressed, and nonpatient smokers. Am. J. Psychiatry 160, 316-322.
159. Swartz MS, HR Wagner, JW Swanson, TS Stroup, JP McEvoy, JM Canive, D.D. M, F Reimherr, M McGee, A Khan, R Van Dorn, RA Rosenheck and JA Lieberman (2006) Substance use in persons with schizophrenia: Baseline prevalence and correlates from the NIMH CATIE study. J. Nerv. Ment. Dis. 1949 164-172.
160. Tobler PN, CD Fiorillo and W Schultz (2005) Adaptive coding of reward value by dopamine neurons. Science 307, 1642-1645.
161. Ullman L and RP Forsythe (1959) Responses by normal and schizophrenic subjects under positive and negative examiner reinforcement in a probability learning situation. Am. Psychologist 14, 407-408.
162. Vastag B (2004) Brain sabotages sobriety, right on cue: Pavlov's progeny provide pictures of alcoholism. JAMA 291, 1053-1055.
163. Verdoux H, M Mury, G Besancon and M Bourgeois (1996) [Comparative study of substance dependence comorbidity in bipolar, schizophrenic and schizoaffective disorders]. Encephale 22, 95-101.
164. 2 receptors in methamphetamine abusers: Association with metabolism in the orbitofrontal cortex. Am. J. Psychiatry 158, 2015-2021.
165. Volkow ND, GJ Wang, H Begleiter, R Hitzemann, N Pappas, G Burr, K Pascani, C Wong, JS Fowler and AP Wolf (1995) Regional brain metabolic response to lorazepam in subjects at risk for alcoholism. Alcoholism, Clin. Exp. Res. 19, 510-516.
166. Volkow ND, GJ Wang, JS Fowler, J Logan, R Hitzemann, YS Ding, N Pappas, C Shea and K Piscani (1996) Decreases in dopamine receptors but not in dopamine transporters in alcoholics. Alcoholism, Clin. Exp. Res. 20, 1594-1598.
167. Wilder KE, DR Weinberger and TE Goldberg (1998) Operant conditioning and the orbitofrontal cortex in schizophrenia patients: Unexpected evidence for intact functioning. Schizophr. Res. 30, 169-174.
168. Xie H, GJ McHugo, BS Helmstetter and RE Drake (2005) Three-year recovery outcomes for long-term patients with co-occurring schizophrenic and substance use disorders. Schizophr. Res. 75, 337-348.
169. 2 receptors in the ventral striatum and central processing of alcohol cues and craving. Am. J. Psychiatry 161, 1783-1789.